Researchers identified predictors of remission in axial spondyloarthritis (axSpA). The findings appeared in Seminars of Arthritis and Rheumatism.
This was a systematic literature review (SLR) by design. The researchers searched through MEDLINE, EMBASE, and Cochrane CENTRAL from their inception to May 20, 2022. Additionally, they assessed abstracts from the 2020 and 2021 American College of Rheumatology and European Alliance of Associations for Rheumatology meetings. The search focused on controlled trials and cohort studies correlated with remission. Overall, the SLR consisted of 21 articles from 4,592 citations.
The results found that only 3 studies analyzed “sustained remission,” and most studies analyzed “point remission.” The investigators noted that Ankylosing Spondylitis Disease Activity Score (ASDAS), and Assessment of SpondyloArthritis international Society partial remission criteria were the most used assessment methods.
The main predictors of remission were younger age, HLA-B27 positivity, male gender, lower baseline Bath Ankylosing Spondylitis Disease Activity Index, lower baseline Bath Ankylosing Spondylitis Functional Index, lower baseline ASDAS-C-reactive protein, treatment with tumor necrosis factor inhibitors, and concomitant use of conventional synthetic disease-modifying anti-rheumatic drugs.
Reference: Pinto AS, Farisogullari B, Machado PM. Predictors of remission in people with axial spondyloarthritis: a systematic literature review [published online ahead of print, 2022 Jul 27]. Semin Arthritis Rheum. 2022;56:152078. doi:10.1016/j.semarthrit.2022.152078
